A clinical trial of a promising new experimental therapy for metastatic melanoma has shown positive results, including tumour shrinkage in the majority of patients. The positive results support previously reported positive data for the drug known as PLX4032 (RG7204) in a much larger patient population where all responses were confirmed by an independent review committee.
Jeffrey Sosman, MD, director of the Melanoma Program at Vanderbilt-Ingram Cancer Center, presented the data from
No comments:
Post a Comment